The exploration of other potential anticancer ligands, such as kallistatin, DENTAC and AS, targeting surface NCL in various cancers, presents a clear opportunity to evaluate their effectiveness in lung cancer specifically. This evidence concerns the gene NUCLEOLIN and cancer.